Our Science

Ensifentrine is a novel PDE3 and 4 inhibitor

We are developing ensifentrine, the first inhaled treatment for respiratory diseases in a single molecule that inhibits both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) resulting in bronchodilator and non-steroidal anti-inflammatory effects.

Pipeline

Product candidates

We are leveraging the novel profile of ensifentrine to build a robust pipeline of therapeutics for the treatment of chronic respiratory diseases.

A female physician checks in on some medical students who are seated together at a table working on a project. They are each dressed professionally and are focused on the task as they work together.

Focus Areas

Respiratory pipeline

We are developing treatments for chronic respiratory indications with significant unmet needs.

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition without a cure. It damages the airways and lungs, leading to debilitating breathlessness.

Non-Cystic Fibrosis Bronchiectasis (bronchiectasis) is a chronic lung disease with no FDA-approved treatment. Patients suffer from persistent cough, excess sputum production and frequent respiratory infections.

Cystic fibrosis (CF) is a potentially fatal genetic disease characterized by the build-up of thick, sticky mucus and infection that can damage many of the body’s organs.

Asthma is a common chronic inflammatory disease that makes it harder to move air in and out of the lungs.

Research and Medical Grants

Funding available

We are committed to supporting the healthcare community through research and medical grants.

African American female scientist analyzing sample on microscope slide in laboratory.

Developing novel therapeutics for respiratory diseases

We welcome inquires from healthcare professionals.

Close up of female doctor hold woman patient hands help on personal therapy session, psychologist or counselor show understanding and care, support depressed suffering client on treatment